Navigation Links
WaferGen Bio-systems to Present at Upcoming Investment Conferences
Date:9/3/2014

FREMONT, Calif., Sept. 3, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. (Nasdaq: WGBS) today announced that Ivan Trifunovich, President and Chief Executive Officer, will present at the following investment conferences: 

  • Rodman & Renshaw 16th Annual Global Investment Conference (sponsored by H.C. Wainwright) on Wednesday, September 10, 2014 at 4:10 p.m. Eastern Time in New York, NY. 
  • Aegis Capital 2014 Healthcare & Technology Conference on Friday, September 12th at 2:30 p.m. Pacific Time in Las Vegas, NV. 

The presentations will be webcast and available live and can be accessed on the Investor Relations section of the corporate website at http://www.wafergen.com/company/investor-relations/financial-information/.  For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.

About WaferGen

WaferGen Bio-systems, Inc. is a life science company that offers innovative genomic solutions for clinical testing and research.  The SmartChip MyDesign™ Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping.  The SmartChip TE™ System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS).  The Company also offers the Apollo 324™ product line used in library preparation for NGS.  These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.  Forward-looking statements may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Investor Contacts:

ICR, Inc.
Bob Yedid
bob.yedid@icrinc.com
646-277-1250

Proactive Capital
Jeff Ramson
jramson@proactivecrg.com
646-863-6893

WaferGen Bio-systems, Inc.
Ivan Trifunovich
ivan.trifunovich@wafergen.com
(510) 651-4450


'/>"/>
SOURCE WaferGen Bio-systems, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
2. WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference
3. WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. WaferGen Bio-systems Awarded 1 Million Euro Grant by the Luxembourg Government to expand its European Operations
6. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
7. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
8. WaferGen Partners with Salk Institute to Establish a Nano-qPCR Core Lab
9. WaferGen Bio-systems Reports Q3 13 Results and Commercial Focus on Target Enrichment for Next-Gen Sequencing (NGS)
10. WaferGen Bio-systems Acquires a Leading Next-Generation Sequencing (NGS) Library Preparation Business and Announces Changes to its Board of Directors
11. WaferGen Bio-systems Announces Second Quarter 2014 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its ... ended September 30, 2016. ... , SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... Colorado (PRWEB) , ... December 06, 2016 , ... ... dynamic aqueous plasma technology platforms, announced today that the company has engaged in ... Research and Development Agreement (MRDA) with the CSU Office of the Vice President ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International has ... million from the National Institutes of Health,s National ... Division of AIDS (NIAID-DAIDS) to support the manufacturing ... pre-exposure (PreP) agents. Under the seven-year contract, SRI ... development services for candidate HIV-prevention products that emerge ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition claims are ... There are also claims directed to combination with polymers, carbon fibers, graphene, and ...
Breaking Biology Technology:
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):